Prise en charge des hémangiomes infantiles en milieu communautaire
Résumé
Je suis dermatologue généraliste dans le nord de la Colombie-Britannique. Au cours de ma première année de pratique, j’ai vu plusieurs nourrissons qui avaient besoin d’un traitement pour un hémangiome infantile, ce qui m’a obligé à me familiariser avec les traitements topiques et systémiques. Cet article a pour objectif de fournir une vue d’ensemble de la prise en charge des hémangiomes infantiles non compliqués en milieu communautaire, afin d’aider les dermatologues à prescrire en toute confiance les traitements topiques et systémiques de première intention.
Références
Sun Y, Zhao J, Meng Y, Luo W, Jiang C, Deng G, et al. The prevalence, complications, and risk factors for infantile hemangioma: a systematic review and meta-analysis. Int J Dermatol. 2024;63(6):737-746. doi:10.1111/ijd.17062
Ding Y, Zhang JZ, Yu SR, Xiang F, Kang XJ. Risk factors for infantile hemangioma: a meta-analysis. World J Pediatr. 2020;16(4):377-384. doi:10.1007/s12519-019-00327-2
Rodríguez Bandera AI, Sebaratnam DF, Wargon O, Wong LF. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021;85(6):1379-1392. doi:10.1016/j.jaad.2021.08.019
Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367. doi:10.1542/peds.2007-2767
Paller AS, Mancini AJ. Infantile hemangiomas, vascular malformations, and other vascular disorders of infancy and childhood. In: Paller AS, Mancini AJ, editors. Hurwitz Clinical Pediatric Dermatology. 5th ed. Philadelphia: Elsevier; 2020. p. 326-368.e8.
Baselga E, Roe E, Coulie J, Munoz FZ, Boon LM, McCuaig C, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol. 2016;152(11):1239-1243. doi:10.1001/jamadermatol.2016.2905
Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475
Püttgen K, Lucky A, Adams D, Pope E, McCuaig C, Powell J, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016;138(3):e20160355. doi:10.1542/peds.2016-0355
Solman L, Glover M, Beattie PE, Buckley H, Clark S, Gach JE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179(3):582-589. doi:10.1111/bjd.16779
Smithson SL, Rademaker M, Adams S, Bade S, Bekhor P, Davidson S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 2017;58(2):155-159. doi:10.1111/ajd.12600
Pierre Fabre Dermo-Cosmétique Canada Inc. Product monograph including patient medication information Pr HEMANGIOL (propranolol solution). Oral solution, 3.75 mg/mL propranolol (as propranolol hydrochloride), oral use. Brossard, QC, Canada. [Authorization 2021 Jun 16, Revision 16 Jun 2021]. Available from: https://www.hemangiol.ca/pm/
Sebaratnam DF, Rodríguez Bandera AL, Wong LF, Wargon O. Infantile hemangioma. part 2: management. J Am Acad Dermatol. 2021;85(6):1395-1404. doi:10.1016/j.jaad.2021.08.020
Frieden IJ, Püttgen KB, Drolet BA, Garzon MC, Chamlin SL, Pope E, et al. Management of infantile hemangiomas during the COVID pandemic. Pediatr Dermatol. 2020;37(3):412-418. doi:10.1111/pde.14196
Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016;137(4):e20151754.
Pope E, Lara-Corrales I, Sibbald C, Liy-Wong C, Kanigsberg N, Drolet B, et al. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatrics. 2022;176(1):34-41. doi:10.1001/jamapediatrics.2021.4565
